Human Genome Says Cancer Drug is Safe
Posted on: Wednesday, 8 November 2006, 12:01 CST
Human Genome Sciences has said a phase Ib clinical trial demonstrates that HGS-ETR1 in combination with gemcitabine and cisplatin was well tolerated and could be administered safely in patients with advanced solid tumors.
"Preclinical studies have shown that adding HGS-ETR1 to gemcitabine and cisplatin results in increased cytotoxicity. These data warrant further study of HGS-ETR1 in combination with chemotherapeutic agents in phase II trials to evaluate its potential for use in the treatment of specific cancers," said Professor Dr Elisabeth de Vries, head of the division of medical oncology, Groningen University Hospital, The Netherlands.
The primary objective of the study, which is being conducted in the Netherlands, is to evaluate the safety and tolerability of escalating doses of the combination of gemcitabine and cisplatin.
Human Genome Sciences commented that the maximum tolerated dose of HGS-ETR1 has not yet been reached and patients will continue to be enrolled in the phase Ib study.
Source: Datamonitor
Related Articles
- Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
- Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
- Human Genome Sciences Reports Interim Results of Phase 1b Clinical Trial of HGS-ETR1 With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
- Human Genome Sciences Initiates Randomized Phase 2 Clinical Trial of HGS-ETR1 in Combination With Bortezomib
- Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In Patients With Advanced Colorectal Cancer
- Human Genome Sciences Reports Results of Phase 2 Clinical Trial of HGS-ETR1 In Patients With Non-Small Cell Lung Cancer
- Human Genome Sciences Reports Results of Phase 1 Clinical Trial of HGS-ETR1 in Patients With Advanced Solid Tumors
- Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Non-Hodgkin's Lymphoma
- Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Colorectal Cancer
- Human Genome Sciences Completes Patient Enrollment in A Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Non-Small Cell Lung Cancer
User Comments (0)

RSS Feeds